Antithrombin III for critically ill patients (Q24242053)

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Antithrombin treatment in patients with traumatic brain injury: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Antithrombin III and local serum application: adjuvant therapy in peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Substitution of antithrombin III in shock and DIC: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Antithrombin III in patients with severe sepsis: a pharmacokinetic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Antithrombin III in patients admitted to intensive care units: a multicenter observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

The effect of substitution with AT III- and PPSB-concentrates in patients with terminal liver insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Lipoprotein metabolism in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Clinical trial results with antithrombin III in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Why we need a broad perspective on meta-analysis. It may be crucially important for patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

21 January 2018

Vasopressors for shock

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Antithrombin, heparin, and heparan sulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Clinical Trial Design and Outcomes in Patients with Severe Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Current treatment of sepsis and endotoxaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Overcoming the limitations of current meta-analysis of randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Drug intervention trials in sepsis: divergent results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

The anti-inflammatory actions of antithrombin--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Use of antithrombin III in critical patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Modulation of coagulation and fibrinolysis in hepatic resection: a randomized prospective control study using antithrombin III concentrates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Treatment with antithrombin III (AT III) concentrate in pre-eclampsia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Controlled trial of antithrombin III supplementation in fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Is there a need for antithrombin III substitution early after burn injury?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Antithrombin(H) concentrate infusions are safe and effective in patients with thermal injuries

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

High-dose antithrombin III treatment of severely injured patients: results of a prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Effect of antithrombin concentrate on haemostatic variables in critically ill patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Single-shot antithrombin in human pancreas-kidney transplantation: reduction of reperfusion pancreatitis and prevention of graft thrombosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Antithrombin-III substitution in preterm infants--effect on intracranial hemorrhage and coagulation parameters

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well-controlled multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Efficacy of AT in pre-eclampsia: a case-control prospective trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Antithrombin can modulate coagulation, cytokine production, and expression of adhesion molecules in abdominal aortic aneurysm repair surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005370.PUB2

7 January 2021

10.1002/14651858.CD005370.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

18646125

1 reference

Consolidated OpenCitations Corpus – April 2017